Updates from the SELECT Trial: Outcomes by Sex | ESC 2024
Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Subodh Verma MD, PhD explore a secondary analysis of the SELECT trial, a landmark study investigating the cardiovascular benefits of semaglutide...
30 Aug 202418min
Updates from the STEP-HFpEF Trial | ESC 2024
Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Mikhail Kosiborod, MD, FACC discuss an exciting secondary analysis of the STEP-HFpEF program, shedding light on the groundbreaking findings rela...
30 Aug 202421min
An Analysis From the SELECT Trial - COVID-19| ESC 2024
Harlan Krumholz, MD, FACC, JACC Editor-in-Chief, and Benjamin M. Scirica, MD, MPH, FACC, discuss the surprising benefits of semaglutide beyond weight loss and cardiovascular health from the SELECT tri...
30 Aug 20246min
Insights from the FLOW Trial | ESC 2024
Neha J. Pagidipati, MD, FACC, JACC Associate Editor, and Richard Pratley, MD, discuss insights from the FLOW trial – revealing that semaglutide reduced heart failure events and cardiovascular death by...
30 Aug 202410min
Antithrombotic Strategies for Patients with Peripheral Artery Disease: JACC Scientific Statement
In the September 3rd, 2024 issue of JACC, a new scientific statement delves into antithrombotic strategies for peripheral artery disease (PAD), highlighting the challenges and advancements in treatmen...
26 Aug 202422min
Continuous Rhythm Monitoring with Implanted Loop Recorders in Children and Adolescents with Brugada Syndrome
In the September 3, 2024, issue of JACC, Dr. Valentin Fuster introduces a pivotal study on Brugada syndrome in children and adolescents. This research, led by Dr. Marco Berganti and colleagues, demons...
26 Aug 202410min
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM
In the September 3, 2024, JACC issue, a major study evaluates the cardiovascular outcomes of second-line antihyperglycemic agents in type 2 diabetes, comparing SGLT2 inhibitors, GLP-1 receptor agonist...
26 Aug 202411min
Anticoagulation Alone vs Anticoagulation Plus Aspirin or DAPT Following Watchman FLX Left Atrial Appendage Occlusion
In the September 3, 2024, issue of JACC, Dr. Samuel Reinhart and team find that using direct oral anticoagulants alone is associated with fewer adverse events compared to combining them with aspirin a...
26 Aug 20248min
